Pfizer gains paediatric PAH label for Revatio in Europe
This article was originally published in Scrip
Executive Summary
The European Commission has approved Pfizer's Revatio (sildenafil) for the treatment of pulmonary arterial hypertension (PAH) in paediatric patients aged 1 to 17 years old.